Tirzepatide

FDA-approved product existsMetabolic ResearchWeight & metabolic
6.1

Worth trying, BioHarmony verdict

BioHarmony score 6.1 out of 10

Tirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects. Jastreboff 2022 established major body-weight reduction in adults with obesity, Frias 2021 showed superiority to semaglutide 1 mg for type 2 diabetes glycemia, and…

Read full report

What is Tirzepatide?

Tirzepatide is a once-weekly injectable peptide pharmaceutical that activates both glucose-dependent insulinotropic polypeptide receptors and glucagon-like peptide-1 receptors. The practical effects are reduced appetite, improved glucose-dependent insulin secretion, altered glucagon signaling, delayed gastric emptying, and lower body weight. In the pivotal obesity program, Jastreboff 2022 showed substantial weight reduction versus placebo in adults with obesity or overweight without diabetes. In type 2 diabetes, Frias 2021 showed greater glycemic and weight effects than semaglutide 1 mg.

From the BioHarmony report, reviewed Sep 19, 2026.

Saved on this device only.

Safety watch-outs

  • Persistent vomiting or dehydration
  • Severe abdominal pain
  • Blood in stool or black stool
  • Symptoms of pancreatitis: severe upper abdominal pain radiating to back
  • Right upper quadrant pain, fever, jaundice, or pale stools (gallbladder)

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelZEPBOUND prescribing information for approved weight-management and obstructive-sleep-apnea indications
PopulationAdults covered by the approved ZEPBOUND indications
DoseStart at 2.5 mg once weekly for 4 weeks, then 5 mg once weekly. The label permits 2.5 mg increases after at least 4 weeks on the current dose; maintenance doses vary by indication and the maximum is 15 mg once weekly.
RouteSubcutaneous injection in the abdomen, thigh, or back of the upper arm
FrequencyOnce weekly
DurationLong-term use within the approved indications; escalation intervals are at least 4 weeks
PreparationReady-to-use solution supplied in single-dose pens or vials and multi-dose vials or KwikPens; no reconstitution. The label lists presentation-specific concentrations and volumes.
Source: Dosage and Administration sections 2.1-2.4; Dosage Forms and Strengths section 3

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (2)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingCompounded products are not FDA approved and eligibility is circumstance-specific

FDA lists approved tirzepatide products and warns that unapproved versions do not undergo FDA review for safety, effectiveness, or quality before marketing. FDA had received more than 730 adverse-event reports associated with compounded tirzepatide as of May 31, 2026.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.